cilostazol has been researched along with Coronary Heart Disease in 36 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 9.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| "120 in-hospital coronary heart disease patients with coronary stenting were randomized to two groups receiving either triple antiplatelet drugs of aspirin and clopidogrel combined with cilostazol or dual antiplatelet drugs of aspirin and clopidogrel." | 5.12 | [The effects of post coronary stenting triple antiplatelet therapies on platelet functions]. ( Han, YL; Kang, J; Li, Y; Su, QF; Wang, SL; Yan, CH, 2006) |
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 5.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| "Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use." | 2.72 | A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. ( Chen, YD; Jin, ZN; Lü, SZ; Lu, YL; Yuan, F, 2006) |
| "Aspirin 100 mg/d was administrated concomitantly with cilostazol or ticlopidine." | 2.71 | [Effects of cilostazol on long-term clinical outcomes after coronary stenting]. ( Deng, J; Ge, JB; Han, YL; Jing, QM; Li, Y; Ma, YY; Wang, SL; Yang, GT; Yu, HB, 2005) |
| "Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use." | 2.70 | Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. ( Inoue, T; Kamishirado, H; Mizoguchi, K; Morooka, S; Nakata, T; Sakuma, M; Takayanagi, K; Uchida, T, 2002) |
| "Cilostazol is an antiplatelet agent that increases the intracellular concentration of cyclic adenosine monophosphate by inhibiting phosphodiesterase III; it has been shown to reduce neointimal hyperplasia in animal balloon injury models." | 2.70 | Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. ( Ayabe, S; Hara, K; Ikari, Y; Kozuma, K; Kuroda, Y; Morino, Y; Tamura, T; Tanabe, K; Yamasaki, M, 2001) |
| "Cilostazol is a potent antiplatelet agent with less serious side effects." | 2.69 | Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999) |
| "Cilostazol 200 mg/day was administered for 3 months (31 patients) or 6 months (37 patients), and coronary flow reserve were measured before and after the cilostazol administration." | 2.69 | [Effect of long-term cilostazol administration on coronary flow velocity and coronary flow reserve]. ( Kira, Y; Muneyuki, T; Oka, Y; Sada, T; Tanaka, T, 1999) |
| "Cilostazol is a potent antiplatelet agent with antiproliferative properties." | 2.69 | Effects of cilostazol on angiographic restenosis after coronary stent placement. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, NH; Nah, DY; Park, SJ; Park, SW, 2000) |
| "To prevent restenosis, 46 patients (60 PTCA sites) were treated with cilostazol alone (200 mg/day) (cilostazol group) and the remaining 56 (61 PTCA sites) were treated with other anti-platelet drugs and/or warfarin potassium (control group)." | 2.68 | Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty. ( Hayashida, K; Higuchi, S; Kuga, T; Matsuguchi, T; Okamatsu, S; Shimokawa, H; Sobashima, A; Tsutsui, M; Yoshihara, S, 1996) |
| "Cilostazol is a vasodilating antiplatelet agent that reversibly inhibits platelet aggregation induced by many factors." | 2.41 | Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. ( El-Beyrouty, C; Spinler, SA, 2001) |
| "Cilostazol is an effective antiplatelet agent with minimum side effects after elective, bailout, or primary stent implantation." | 1.30 | Antiplatelet treatment with cilostazol after stent implantation. ( Kojima, S; Kuramochi, M; Matsumoto, Y; Sugi, T; Yano, M; Yoshitomi, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 10 (27.78) | 18.2507 |
| 2000's | 21 (58.33) | 29.6817 |
| 2010's | 4 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, XT | 1 |
| Chen, KY | 1 |
| Liu, T | 1 |
| Xu, LX | 1 |
| Che, JJ | 1 |
| Rha, SW | 2 |
| Li, GP | 1 |
| Jeong, YH | 2 |
| Lee, SW | 2 |
| Choi, BR | 1 |
| Kim, IS | 2 |
| Seo, MK | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Park, SW | 5 |
| Yasuda, H | 1 |
| Yamada, M | 1 |
| Sawada, S | 1 |
| Endo, Y | 1 |
| Inoue, K | 1 |
| Asano, F | 1 |
| Takeyama, Y | 1 |
| Yoshiba, M | 1 |
| Goto, S | 1 |
| Toda, E | 1 |
| Suh, JW | 1 |
| Lee, SP | 1 |
| Park, KW | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Bae, JH | 1 |
| Kwon, TG | 1 |
| Bae, JW | 1 |
| Cho, MC | 1 |
| Kim, HS | 3 |
| Yang, TH | 1 |
| Kim, DI | 1 |
| Kim, DK | 2 |
| Jang, JS | 1 |
| Kim, U | 1 |
| Seol, SH | 1 |
| Hong, GR | 1 |
| Park, JS | 1 |
| Shin, DG | 1 |
| Kim, YJ | 1 |
| Cho, YK | 1 |
| Nam, CW | 1 |
| Hur, SH | 1 |
| Kim, KB | 1 |
| Kim, DS | 1 |
| Bliden, KP | 1 |
| Tantry, US | 1 |
| Park, Y | 1 |
| Gurbel, PA | 1 |
| Kamishirado, H | 1 |
| Inoue, T | 1 |
| Mizoguchi, K | 1 |
| Uchida, T | 1 |
| Nakata, T | 1 |
| Sakuma, M | 1 |
| Takayanagi, K | 1 |
| Morooka, S | 1 |
| Funabiki, K | 1 |
| Masuoka, H | 1 |
| Shimizu, H | 1 |
| Emi, Y | 1 |
| Mori, T | 1 |
| Ito, M | 1 |
| Nakano, T | 1 |
| Okazaki, S | 1 |
| Yokoyama, T | 1 |
| Miyauchi, K | 1 |
| Shimada, K | 1 |
| Kurata, T | 1 |
| Sato, H | 1 |
| Daida, H | 1 |
| Takeyasu, N | 1 |
| Watanabe, S | 1 |
| Noguchi, Y | 1 |
| Ishikawa, K | 1 |
| Fumikura, Y | 1 |
| Yamaguchi, I | 1 |
| Hong, MK | 3 |
| Kim, YH | 1 |
| Lee, BK | 1 |
| Song, JM | 1 |
| Han, KH | 1 |
| Lee, CW | 3 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Kim, JJ | 3 |
| Park, SJ | 3 |
| Han, YL | 3 |
| Wang, SL | 3 |
| Li, Y | 3 |
| Jing, QM | 2 |
| Ma, YY | 2 |
| Deng, J | 1 |
| Yang, GT | 1 |
| Yu, HB | 1 |
| Ge, JB | 1 |
| Chen, YD | 1 |
| Lu, YL | 1 |
| Jin, ZN | 1 |
| Yuan, F | 1 |
| Lü, SZ | 1 |
| Su, QF | 2 |
| Wang, ZL | 1 |
| Wang, DM | 1 |
| Luan, B | 1 |
| Patel, TN | 1 |
| Kreindel, M | 1 |
| Lincoff, AM | 1 |
| Kang, J | 1 |
| Yan, CH | 1 |
| Liao, JK | 1 |
| Min, PK | 1 |
| Jung, JH | 1 |
| Ko, YG | 1 |
| Choi, D | 1 |
| Jang, Y | 2 |
| Shim, WH | 2 |
| Tsutsui, M | 1 |
| Shimokawa, H | 1 |
| Higuchi, S | 1 |
| Yoshihara, S | 1 |
| Hayashida, K | 1 |
| Sobashima, A | 1 |
| Kuga, T | 1 |
| Matsuguchi, T | 1 |
| Okamatsu, S | 1 |
| Take, S | 1 |
| Matsutani, M | 1 |
| Ueda, H | 1 |
| Hamaguchi, H | 1 |
| Konishi, H | 1 |
| Baba, Y | 1 |
| Kawaratani, H | 1 |
| Sugiura, T | 1 |
| Iwasaka, T | 1 |
| Inada, M | 1 |
| Tsuchikane, E | 2 |
| Katoh, O | 1 |
| Sumitsuji, S | 1 |
| Fukuhara, A | 2 |
| Funamoto, M | 1 |
| Otsuji, S | 2 |
| Tateyama, H | 2 |
| Awata, N | 2 |
| Kobayashi, T | 3 |
| Sekiya, M | 1 |
| Funada, J | 1 |
| Watanabe, K | 1 |
| Miyagawa, M | 1 |
| Akutsu, H | 1 |
| Yamasaki, M | 2 |
| Hara, K | 2 |
| Ikari, Y | 2 |
| Kobayashi, N | 1 |
| Kozuma, K | 2 |
| Ohmoto, Y | 1 |
| Oh-Hashi, Y | 1 |
| Ako, J | 1 |
| Nakajima, H | 1 |
| Chiku, N | 1 |
| Saeki, F | 1 |
| Tamura, T | 2 |
| Yoshitomi, Y | 1 |
| Kojima, S | 1 |
| Sugi, T | 1 |
| Yano, M | 1 |
| Matsumoto, Y | 1 |
| Kuramochi, M | 1 |
| Kirino, M | 1 |
| Yamasaki, K | 1 |
| Izumi, M | 1 |
| Sakurai, M | 1 |
| Lee, HJ | 1 |
| Park, HK | 1 |
| Tanaka, T | 1 |
| Muneyuki, T | 1 |
| Oka, Y | 1 |
| Sada, T | 1 |
| Kira, Y | 1 |
| Yoon, Y | 1 |
| Lee, DH | 1 |
| Pyun, WB | 1 |
| Kim, IJ | 1 |
| Cho, SY | 1 |
| Lee, NH | 1 |
| Nah, DY | 1 |
| Morino, Y | 1 |
| Ayabe, S | 1 |
| Kuroda, Y | 1 |
| Tanabe, K | 1 |
| Ahn, CW | 1 |
| Lee, HC | 1 |
| Song, YD | 1 |
| Huh, KB | 1 |
| Oh, SJ | 1 |
| Kim, YS | 1 |
| Choi, YK | 1 |
| Kim, JM | 1 |
| Lee, TH | 1 |
| Nagaoka, N | 1 |
| Matsubara, T | 1 |
| Okazaki, K | 1 |
| Masuda, N | 1 |
| Shikaura, K | 1 |
| Hotta, A | 1 |
| Tanabe, Y | 1 |
| Ito, E | 1 |
| Nakagawa, I | 1 |
| Suzuki, K | 1 |
| El-Beyrouty, C | 1 |
| Spinler, SA | 1 |
| Murohara, Y | 1 |
| Takatsu, Y | 1 |
| Yui, Y | 1 |
| Kawai, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound[NCT01200056] | Phase 4 | 40 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
3 reviews available for cilostazol and Coronary Heart Disease
| Article | Year |
|---|---|
Cholesterol crystal embolization (CCE) after cardiac catheterization: a case report and a review of 36 cases in the Japanese literature.
Topics: Aged; Blue Toe Syndrome; Cardiac Catheterization; Cholecystitis; Cilostazol; Coronary Angiography; C | 2003 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cilostazol; Coronary Disease; Coronary Restenosis; | 2001 |
22 trials available for cilostazol and Coronary Heart Disease
| Article | Year |
|---|---|
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
Topics: Cilostazol; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Plate | 2009 |
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
Topics: Cilostazol; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Plate | 2009 |
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
Topics: Cilostazol; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Plate | 2009 |
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
Topics: Cilostazol; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Plate | 2009 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
Topics: Aged; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Therapy | 2002 |
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atorvastatin; Cardiova | 2004 |
Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting.
Topics: Aged; Cilostazol; Coronary Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; | 2005 |
[Effects of cilostazol on long-term clinical outcomes after coronary stenting].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Drug Therapy, Co | 2005 |
A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent.
Topics: Adult; Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Disease; Double-Blind Method; F | 2006 |
[Short-term outcomes of triple antiplatelet therapy after percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Drug Thera | 2006 |
[The effects of post coronary stenting triple antiplatelet therapies on platelet functions].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Drug Therapy, Combinati | 2006 |
Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Vessels; Dr | 2007 |
Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Cilostazol; Constriction, Pathologic; Coronary Disease; Corona | 1996 |
Impact of cilostazol on intimal proliferation after directional coronary atherectomy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherectomy, Coronary; Cell Division; Cilostazol; Cor | 1998 |
Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cilostazol; Coronary Angiography; C | 1998 |
Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation.
Topics: Aged; Animals; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Dogs; Female; Follow-Up | 1998 |
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Calcium; Cell Division; Cilostazol; Combined Modality | 1999 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
[Effect of long-term cilostazol administration on coronary flow velocity and coronary flow reserve].
Topics: Administration, Oral; Aged; Blood Flow Velocity; Cilostazol; Coronary Circulation; Coronary Disease; | 1999 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Effects of cilostazol on angiographic restenosis after coronary stent placement.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Disease | 2000 |
Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation.
Topics: Cilostazol; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Ana | 2001 |
Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Blood Pressure; Carotid Artery, Common; Cilostazol; Coronary Disease; Diabetes Mellit | 2001 |
Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Cilostazol; Coronary Angiography; Coronary Disease; Female; Fo | 2001 |
11 other studies available for cilostazol and Coronary Heart Disease
| Article | Year |
|---|---|
Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Int | 2016 |
Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Co | 2009 |
Antiplatelet therapy after coronary intervention in Asia and Japan: the Asian perspective of antiplatelet intervention.
Topics: Asia; Cerebral Hemorrhage; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Coronary Disease; Eur | 2009 |
Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Cilostazol; Clopidogrel; Cor | 2011 |
We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity.
Topics: Administration, Oral; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Blood Platelets; Cilosta | 2011 |
Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; | 2005 |
Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
Topics: ADAM Proteins; ADAMTS1 Protein; Aged; Apoptosis; Aspirin; Autoantibodies; Cilostazol; Clopidogrel; C | 2006 |
Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Cilostazol; Coronary Disease; Female; Humans; Male; Middle Age | 1997 |
Antiplatelet treatment with cilostazol after stent implantation.
Topics: Aged; Cilostazol; Coronary Disease; Coronary Thrombosis; Evaluation Studies as Topic; Female; Follow | 1998 |
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Cilos | 2001 |
[The mode of action and clinical applications of phosphodiesterase inhibitors as anti-platelet drugs].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cilostazol; Coronary Disease; Coronary Thrombosis; Cyclic AMP; | 1989 |